Non Alcoholic Fatty Liver Disease Clinical Trial
Official title:
Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity
This prospective randomized trial evaluates the role of customized dietary and physical
activity intervention on the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) in
patients with obesity and presenting at least three of the main Metabolic Syndrome traits.
The project proposes a personalized nutritional intervention based on a Mediterranean
customized diet which introduces plenty of antioxidant and anti-inflammatory bioactive
components, coupled with physical activity promotion to prevent and reverse NAFLD among obese
patients with metabolic syndrome. This will be compared with two more dietary strategies
including a Mediterranean Diet intervention with seven meals a day and the conventional
dietary approach proposed by the American Association for the Study of Liver Diseases
(AASLD).
There is currently no licensed pharmacological treatment for reversing Non-Alcoholic Fatty
Liver Disease (NAFLD), this is why nutritional and lifestyle strategies are pivotal to
ameliorate risk factors and prevent disease progression. Weight loss achieved by a weight
loss diet and exercise is certainly the principal treatment for the amelioration of fatty
liver, nevertheless quality of diet composition could also play a crucial role. Since
oxidative stress and inflammation have been cited among the mechanisms involved in NAFLD,
foods containing antioxidant and anti-inflammatory bioactive components should be considered
when designing a nutritionally sound diet. The Mediterranean Diet, naturally rich in
antioxidants and antinflammatory foods, together with personalised physical activity could
have a variety of positive health effects, including the slowing down of degenerative
diseases such as liver steatosis.
The present study aims to compare and evaluate the efficacy of three interventions on the
pathophysiological mechanisms that may affect changes in liver fat deposits and progression
of NAFLD in patients with obesity and presenting at least three of the main Metabolic
Syndrome traits.
The first intervention group receives a caloric restricted Mediterranean Diet coupled with
physical activity (delivered through guided gym classes); the second group receives a caloric
restricted Mediterranean Diet distributed over 7 meals and advise to walk 10.000 steps a day;
the third group receives the conventional diet proposed by the American Association for the
Study of Liver Diseases (AASLD) and advise to walk 10.000 steps a day.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02248311 -
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
|
N/A | |
Completed |
NCT01277237 -
The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
|
Phase 3 | |
Completed |
NCT01999101 -
Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
|
Phase 2 | |
Completed |
NCT01327443 -
Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
|
N/A | |
Active, not recruiting |
NCT01482065 -
The Sleep, Liver Evaluation and Effective Pressure Study
|
N/A | |
Completed |
NCT03135873 -
Mastiha Treatment for Obese With NAFLD Diagnosis
|
N/A | |
Completed |
NCT02686476 -
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT02820285 -
Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH
|
N/A | |
Completed |
NCT01556113 -
Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
|
N/A | |
Recruiting |
NCT06080386 -
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
|
||
Terminated |
NCT02134522 -
The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease
|
N/A | |
Completed |
NCT01553500 -
Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT05426382 -
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT03300661 -
Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine
|
N/A | |
Not yet recruiting |
NCT02178839 -
The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease
|
N/A | |
Recruiting |
NCT02038387 -
Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)
|
N/A | |
Completed |
NCT01874249 -
Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease
|
N/A | |
Completed |
NCT01634048 -
The Effect of Protein-enriched Diet on Body Composition and Appetite
|
N/A | |
Completed |
NCT01966627 -
Genetics of Fatty Liver Disease in Children
|
N/A | |
Terminated |
NCT01842282 -
Amlexanox for Type 2 Diabetes and Obesity
|
Phase 2 |